Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • navitoclax (ABT 263) • Oncaspar liquid (pegaspargase) • nelarabine • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)

Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)

P1, N=40, Completed, Wake Forest University Health Sciences | Unknown status --> Completed | Phase classification: P2 --> P1

7 days ago

Trial completion • Phase classification

cytarabine • daunorubicin • Starasid (cytarabine ocfosfate)

VITAL: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia (clinicaltrials.gov)

P2, N=42, Active, not recruiting, Vanderbilt-Ingram Cancer Center | Trial completion date: Apr 2024 --> Sep 2024

9 days ago

Trial completion date • Combination therapy • Tumor mutational burden

SRC (SRC Proto-Oncogene)

cytarabine • Qinprezo (vosaroxin) • Starasid (cytarabine ocfosfate)

13d

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma (clinicaltrials.gov)

P2, N=137, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Mar 2024

13 days ago

Trial completion • Trial completion date • Combination therapy

ALK (Anaplastic lymphoma kinase)

ALK positive

Xalkori (crizotinib) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • Adcetris (brentuximab vedotin) • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)

13d

Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients (clinicaltrials.gov)

P2, N=100, Recruiting, Wake Forest University Health Sciences | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025

13 days ago

Trial completion date • Trial primary completion date • Combination therapy

cytarabine • Xpovio (selinexor) • daunorubicin • Starasid (cytarabine ocfosfate)

13d

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma (clinicaltrials.gov)

P1, N=49, Completed, Wake Forest University Health Sciences | Phase classification: P2 --> P1

13 days ago

Phase classification

cytarabine • mitoxantrone • Bylantra (devimistat) • Starasid (cytarabine ocfosfate)

18d

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (clinicaltrials.gov)

P2, N=171, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Apr 2024 --> Jul 2024

18 days ago

Trial initiation date • Combination therapy

MCL1 (Myeloid cell leukemia 1) • KMT2A (Lysine Methyltransferase 2A) • BCL2L1 (BCL2-like 1)

BCL2 expression

Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (recombinant Erwinia asparaginase) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)

18d

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) (clinicaltrials.gov)

P2, N=154, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Apr 2024 --> Aug 2024

18 days ago

Trial initiation date

18d

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)

P3; Initiation date: Apr 2024 --> Jul 2024

18 days ago

Trial initiation date

ABL1 (ABL proto-oncogene 1) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • CD19 (CD19 Molecule) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CSF1R (Colony stimulating factor 1 receptor)

CD19 expression

TruSight RNA Pan-Cancer Panel

dasatinib • imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Starasid (cytarabine ocfosfate)

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)

P1, N=32, Recruiting, OHSU Knight Cancer Institute | Trial completion date: Aug 2024 --> Feb 2026 | Trial primary completion date: Feb 2024 --> Aug 2025

1 month ago

Trial completion date • Trial primary completion date

TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • MECOM (MDS1 And EVI1 Complex Locus) • NUP214 (Nucleoporin 214) • GATA2 (GATA Binding Protein 2) • MLLT3 (MLLT3 Super Elongation Complex Subunit) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • DEK (DEK Proto-Oncogene) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)

TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation

cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)

AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov)

P2, N=80, Recruiting, Children's Oncology Group | Active, not recruiting --> Recruiting

1 month ago

Enrollment open

KMT2A (Lysine Methyltransferase 2A) • CD22 (CD22 Molecule)

MLL rearrangement • CD22 expression

cytarabine • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • Asparlas (calaspargase pegol-mknl) • Starasid (cytarabine ocfosfate)

AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov)

P3, N=1895, Active, not recruiting, National Cancer Institute (NCI)

1 month ago

Trial completion date

CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD22 (CD22 Molecule) • CD34 (CD34 molecule) • CD5 (CD5 Molecule) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule) • MPO (Myeloperoxidase)

CD22 expression

cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • nelarabine • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • dexamethasone injection

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov)

P2, N=80, Recruiting, Mayo Clinic | N=55 --> 80

1 month ago

Enrollment change

IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)

IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation

cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • dexamethasone injection

2ms

A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia (clinicaltrials.gov)

P2, N=78, Recruiting, Children's Oncology Group | Active, not recruiting --> Recruiting

2 months ago

Enrollment open • Combination therapy

KMT2A (Lysine Methyltransferase 2A)

MLL rearrangement

cytarabine • methotrexate • vincristine • revumenib (SNDX-5613) • fludarabine IV • Asparlas (calaspargase pegol-mknl) • Starasid (cytarabine ocfosfate)

2ms

P2, N=171, Not yet recruiting, National Cancer Institute (NCI)

2 months ago

New P2 trial • Combination therapy

MCL1 (Myeloid cell leukemia 1) • KMT2A (Lysine Methyltransferase 2A) • BCL2L1 (BCL2-like 1)

BCL2 expression

2ms

Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma or CCUS (clinicaltrials.gov)

P2, N=55, Recruiting, Mayo Clinic | Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Dec 2025

2 months ago

Trial completion date • Trial primary completion date

IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation

cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • dexamethasone injection

2ms

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene (clinicaltrials.gov)

P1, N=28, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Trial completion date: Feb 2024 --> Dec 2027 | Initiation date: Feb 2024 --> Nov 2024 | Trial primary completion date: Feb 2024 --> Dec 2027

2 months ago

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy

FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)

FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL rearrangement • FLT3 wild-type • MLL mutation

daunorubicin • revumenib (SNDX-5613) • Starasid (cytarabine ocfosfate)

2ms

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov)

P3, N=1400, Active, not recruiting, Children's Oncology Group | Recruiting --> Active, not recruiting

2 months ago

Enrollment closed

FLT3 (Fms-related tyrosine kinase 3)

Xospata (gilteritinib) • etoposide IV • methotrexate • Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • mitoxantrone • Rylaze (recombinant Erwinia asparaginase) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • dexrazoxane

2ms

P3; Initiation date: Jan 2024 --> Apr 2024

2 months ago

Trial initiation date

CD19 expression

TruSight RNA Pan-Cancer Panel

2ms

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) (clinicaltrials.gov)

P2, N=153, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025

2 months ago

Trial completion date • Trial primary completion date

TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • RARA (Retinoic Acid Receptor Alpha) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • PML (Promyelocytic Leukemia) • CEBPA (CCAAT Enhancer Binding Protein Alpha)

TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation • CEBPA mutation

Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)

2ms

AALL1732: Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy (clinicaltrials.gov)

P3, N=4997, Recruiting, Children's Oncology Group | Trial completion date: Jun 2029 --> Mar 2030 | Trial primary completion date: Jun 2029 --> Mar 2030

2 months ago

Trial completion date • Trial primary completion date

cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)

2ms

NCI-2018-01078: Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia (clinicaltrials.gov)

P2, N=90, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025

2 months ago

Trial completion date • Trial primary completion date

ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)

cytarabine • Iclusig (ponatinib) • Blincyto (blinatumomab) • methotrexate • Starasid (cytarabine ocfosfate)

2ms

NCI-2018-01813: Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)

P1/2, N=73, Completed, M.D. Anderson Cancer Center | N=200 --> 73

2 months ago

Enrollment change

FLT3 (Fms-related tyrosine kinase 3)

FLT3 mutation

cytarabine • azacitidine • Vanflyta (quizartinib) • Starasid (cytarabine ocfosfate)

3ms

NCI-2019-01726: Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia (clinicaltrials.gov)

P1, N=18, Recruiting, Uma Borate | Trial primary completion date: Jan 2024 --> Jan 2025

3 months ago

Trial primary completion date • Combination therapy

FLT3 (Fms-related tyrosine kinase 3) • CD33 (CD33 Molecule)

CD33 positive • CD33 expression

cytarabine • Rydapt (midostaurin) • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • Starasid (cytarabine ocfosfate)

3ms

A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia (clinicaltrials.gov)

P2, N=78, Active, not recruiting, Children's Oncology Group | Recruiting --> Active, not recruiting

3 months ago

Enrollment closed • Combination therapy

KMT2A (Lysine Methyltransferase 2A)

MLL rearrangement

cytarabine • methotrexate • vincristine • revumenib (SNDX-5613) • fludarabine IV • Asparlas (calaspargase pegol-mknl) • Starasid (cytarabine ocfosfate)

3ms

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)

P2, N=97, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2024 --> Jan 2025

3 months ago

Trial completion date

ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule) • CD5 (CD5 Molecule) • CD79A (CD79a Molecule) • MME (Membrane Metalloendopeptidase) • CD7 (CD7 Molecule) • ANPEP (Alanyl Aminopeptidase, Membrane) • MPO (Myeloperoxidase)

dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)

3ms

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (clinicaltrials.gov)

P2, N=53, Active, not recruiting, Fred Hutchinson Cancer Center | N=80 --> 53

3 months ago

Enrollment change

cytarabine • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate)

3ms

Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia (clinicaltrials.gov)

P1, N=19, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=62 --> 19

3 months ago

Enrollment closed • Enrollment change

cytarabine • fludarabine IV • Asparec (PEGylated recombinant Erwinia chrysantemi-derived L-asparaginase) • Starasid (cytarabine ocfosfate)

3ms

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy (clinicaltrials.gov)

P1, N=36, Not yet recruiting, Children's Oncology Group

3 months ago

New P1 trial

cytarabine • methotrexate • leucovorin calcium • fludarabine IV • Starasid (cytarabine ocfosfate) • imetelstat (GRN163L)

3ms

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. (clinicaltrials.gov)

P2, N=107, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed

3 months ago

Trial completion

ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)

dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • Starasid (cytarabine ocfosfate)

3ms

NCI-2011-03562: Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov)

P2, N=37, Completed, Roswell Park Cancer Institute | Active, not recruiting --> Completed

3 months ago

Trial completion

CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • IGH (Immunoglobulin Heavy Locus) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)

Chr t(11;14) • CD20 expression

cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine • Arzerra (ofatumumab) • Starasid (cytarabine ocfosfate) • dexamethasone injection • methotrexate IV

3ms

Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia (clinicaltrials.gov)

P1/2, N=37, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

3 months ago

Enrollment closed

cytarabine • cladribine • uproleselan sodium (APL-106) • Starasid (cytarabine ocfosfate)

3ms

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (clinicaltrials.gov)

P2, N=80, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting

3 months ago

Enrollment closed

cytarabine • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate)

3ms

ADVL1712: Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)

P1, N=12, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed

3 months ago

Trial completion

cytarabine • azacitidine • methotrexate • pevonedistat (MLN4924) • fludarabine IV • Starasid (cytarabine ocfosfate)

4ms

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov)

P2, N=87, Active, not recruiting, National Cancer Institute (NCI) | N=57 --> 87 | Trial completion date: Dec 2023 --> Jan 2025

4 months ago

Enrollment change • Trial completion date

cytarabine • Starasid (cytarabine ocfosfate)

4ms

VITAL: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia (clinicaltrials.gov)

P2, N=42, Active, not recruiting, Vanderbilt-Ingram Cancer Center | Trial completion date: Jan 2024 --> Apr 2024

4 months ago

Trial completion date • Combination therapy • Tumor mutational burden

SRC (SRC Proto-Oncogene)

cytarabine • Qinprezo (vosaroxin) • Starasid (cytarabine ocfosfate)

4ms

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) (clinicaltrials.gov)

P2, N=154, Not yet recruiting, National Cancer Institute (NCI)

4 months ago

New P2 trial

4ms

NCI-2018-01186: Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov)

P2, N=21, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025

4 months ago

Trial completion date • Trial primary completion date

ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)

Rituxan (rituximab) • cytarabine • Iclusig (ponatinib) • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)

4ms

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (clinicaltrials.gov)

P1, N=120, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2025

4 months ago

Trial completion date • Trial primary completion date

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)

cytarabine • cyclophosphamide • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)

4ms

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia (clinicaltrials.gov)

P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Phase classification: P1b --> P1

4 months ago

Phase classification • Combination therapy

TP53 wild-type

cytarabine • navtemadlin (KRT-232) • idarubicin hydrochloride • Starasid (cytarabine ocfosfate)

4ms

Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov)

P1/2, N=53, Active, not recruiting, University of Southern California | Phase classification: P1b --> P1/2

4 months ago

Phase classification • Combination therapy

cytarabine • idarubicin hydrochloride • pevonedistat (MLN4924) • Starasid (cytarabine ocfosfate)

5ms

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov)

P2, N=270, Recruiting, M.D. Anderson Cancer Center | N=200 --> 270

5 months ago

Enrollment change

cytarabine • decitabine • Mylotarg (gemtuzumab ozogamicin) • idarubicin hydrochloride • fludarabine IV • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)